King raises offer for Alpharma
This article was originally published in Scrip
Executive Summary
King Pharmaceuticals has raised its offer for Alpharma by 12% to $37.00 per share in cash. Last month, Alpharma rejected King's bid of $33.00 per share in cash for all the outstanding Alpharma stock, claiming it significantly undervalued the company (Scrip Online, August 27th, 2008). Brian Markison, King's chairman, president and CEO, said in a letter dated September 11th to Alpharma's president and CEO that King was taking this "enhanced" offer direct to Alpharma stockholders. He also noted that King was prepared to enter into a merger agreement containing a "go-shop" provision, whereby Alpharma would be permitted, after signing, to actively solicit third-party offers during an agreed period of time. Alpharma's board has urged shareholders to take no action and said it would make a recommendation to shareholders within 10 business days following the initiation of the offer. Alpharma shares closed at $37.38 on September 11th, 5% higher than the previous day. Earlier this month Alpharma adopted a limited-duration shareholder rights plan to counter offers for the company (Scrip Online, September 3rd, 2008).
You may also be interested in...
Innovation not M&A to drive Bayer growth in LatAm
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
2010 Scrip 100 - Is Anvisa a friend of innovators?
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan raises $1.5 billion
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.